Publication of Data concerning Cavatak and Evatak in Prostate Cancer
The peer reviewed article entitled, “Potent Oncolytic activity of human enteroviruses against human prostate cancer” has now been published online in advance of print in the international journal “The Prostate”.
The abstract is available at the following link:
The article describes the anti-cancer activity of CAVATAK™, EVATAK™ and CVA21-DAFv
on the growth of a selection of human prostate cancer cells in laboratory cultures. Furthermore,
the article highlights that single intravenous injections of CAVATAK™, EVATAK™ and
CVA21-DAFv produced significant regression of pre-established prostate tumours grown in
Such pre-clinical research data is a key component of the Company capacity to initiate human
Phase I trials using CAVATAK™.
Previous publications made by the Company and its researchers are available on the Company’s
About Viralytics Ltd: Viralytics is listed on the Australian Stock Exchange (ASX code: VLA), Viralytics ADR
trades under VRACY on the OTC market in the USA. Viralytics’ principal asset is the intellectual property relating
to CAVATAK™, an Oncolytic Virus technology. CAVATAK™ is the trade name for Viralytics’ proprietary
formulation of the Coxsackievirus Type A21 (CVA21). CVA21 is a human virus that occurs naturally in the
community. CVA21 has been associated with upper respiratory infection ( “cold” like symptoms) and is self limiting,
requiring no specific treatment for those infected to completely recover. In order to infect a cell, CVA21 must first
attach to the outside of a cell, using a specific ‘receptor’ on the cell’s surface (like a key fitting a lock). CVA21 uses
two receptors to infect cells, intercellular adhesion molecule-1 (ICAM-1) and/or decay accelerating factor (DAF).
Both of these receptor proteins have been demonstrated to be highly expressed on multiple cancer types, including:
melanoma, prostate cancer, breast cancer, multiple myeloma and others
Posted: February 2008